Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled eight approved products for partners, which include leading biopharmaceutical companies.

News
Jun 19, 2014 Data Published in the New England Journal of Medicine Demonstrate that Naloxegol Improved Opioid-Induced Constipation in Chronic Pain Patients »
Jun 12, 2014 US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK »
Jun 11, 2014 Nektar Therapeutics Stock Trading Halted Today; FDA Advisory Committee to Discuss Peripherally-Acting Opioid Receptor Antagonists »
Jun 1, 2014 Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting »
Contact Nektar Investor Relations
Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs
415-482-5585

Jodi Sievers
Associate Director, Investor & Corporate Communications
415-482-5593

Contact
Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877)290-2261
(201)680-6578
www.computershare.com/investor
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide